Market Overview

ARIAD, UK National Cancer Research Institute to Collaborate on SPIRIT 3 Phase 3 Trial

ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) and Newcastle University, U.K.,
on behalf of the U.K. National Cancer Research Institute (NCRI) CML
Working Group, today announced an agreement to collaborate on a
multicenter, randomized Phase 3 trial, named SPIRIT 3, to assess the
impact of switching patients with chronic myeloid leukemia (CML) being
treated with a first-line tyrosine kinase inhibitor, upon suboptimal
response or treatment failure, to ponatinib. The NCRI expects to begin
enrollment in the trial of 1,000 patients at approximately 172 clinical
research sites in the U.K. in the second quarter of 2013.

“The SPIRIT 3 study was designed in partnership with ARIAD to provide
the scientific community and patients living with chronic-phase

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (ARIA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters